

Applicant : Nai-Kong Cheung  
USSN : 10/621,027  
Filed : July 16, 2003  
Examiner : Eric Olson  
Page : 3

Atty. Dkt. No.: 639-B-PCT-US  
Art Unit: 1623  
Date of office action: August 7, 2007  
Date of response: November 6, 2007

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-192 (Canceled).

193. (Currently amended) ~~An anti-cancer pharmaceutical combination~~  
A composition[[,]] comprising:

- (a) ~~a composition comprising an amount of~~ a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; and
  - (b) an orally administered composition comprising a 1,3- $\beta$  glucan derived from barley ~~having a molecular weight of from about 120,000 Da to about 450,000 Da,~~ in an amount effective to enhance the antibody's anti-tumor effect, and at least one pharmaceutically acceptable carrier;
- wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3.

194. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193 wherein compositions (a) and (b) are administered to the subject concurrently or sequentially.

195. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is a monoclonal antibody.

196. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is further

Applicant : Nai-Kong Cheung  
USSN : 10/621,027  
Filed : July 16, 2003  
Examiner : Eric Olson  
Page : 4

Atty. Dkt. No.: 639-B-PCT-US  
Art Unit: 1623  
Date of office action: August 7, 2007  
Date of response: November 6, 2007

capable of activating an antibody dependent cell-mediated cytotoxicity response.

197. (Currently amended) The composition pharmaceutical ~~combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen EGFR.
198. (Currently amended) The composition pharmaceutical ~~combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen GD2.
199. (Currently amended) The composition pharmaceutical ~~combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen GD3.
200. (Currently amended) The composition pharmaceutical ~~combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen CD20.
201. (Currently amended) The composition pharmaceutical ~~combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen HER2.
202. (Currently amended) The composition pharmaceutical ~~combination~~ of claim 193, wherein the cancer cell expressing CD20 is non-Hodgkin's lymphoma, Hodgkin's lymphoma, or Epstein-Barr related lymphoma.
203. (Currently amended) The composition pharmaceutical ~~combination~~ of claim 202, wherein the lymphoma is non-Hodgkin's lymphoma.

Applicant : Nai-Kong Cheung  
USSN : 10/621,027  
Filed : July 16, 2003  
Examiner : Eric Olson  
Page : 5

Atty. Dkt. No.: 639-B-PCT-US  
Art Unit: 1623  
Date of office action: August 7, 2007  
Date of response: November 6, 2007

204. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 197, wherein the cancer cell expressing the EGFR is an epidermoid cancer cell.

205. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 198, wherein the cancer cell expressing the antigen GD2 is a neuroblastoma.

206. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 199, wherein the cancer cell expressing the antigen GD3 is a melanoma cancer cell.

207. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 201, wherein the cancer cell expressing the antigen HER2 is a breast cancer cell.

208-211. (Canceled)

212. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the amount of the orally administered 1,3- $\beta$  glucan is about  $\geq 25$  mg/kg/day, five days a week for a total of 2-4 weeks.

213-218. (Canceled)

219. (Currently amended) ~~An anti-cancer pharmaceutical combination, comprising,~~ A composition comprising:

- (a) ~~a composition comprising an amount of~~ a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; an
- (b) an orally administered composition comprising a 1,3- $\beta$  glucan derived from barley ~~having a molecular weight of from about 120,000 Da to about 450,000 Da,~~ in an amount

Applicant : Nai-Kong Cheung  
USSN : 10/621,027  
Filed : July 16, 2003  
Examiner : Eric Olson  
Page : 6

Atty. Dkt. No.: 639-B-PCT-US  
Art Unit: 1623  
Date of office action: August 7, 2007  
Date of response: November 6, 2007

effective to enhance the antibody's anti-tumor effect,  
and at least one pharmaceutically acceptable carrier;  
wherein the cancer cell is selected from the group  
consisting of neuroblastoma, melanoma, non-Hodgkin's  
lymphoma, breast cancer, Epstein-Barr related lymphoma,  
Hodgkin's lymphoma, and epidermoid carcinoma.

220. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein compositions (a) and (b) are administered to the subject concurrently or sequentially.
221. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is a monoclonal antibody.
222. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.
223. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is directed to EGFR (epidermal growth factor receptor).
224. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is directed to antigen GD2.
225. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is directed to antigen GD3.

Applicant : Nai-Kong Cheung  
USSN : 10/621,027  
Filed : July 16, 2003  
Examiner : Eric Olson  
Page : 7

Atty. Dkt. No.: 639-B-PCT-US  
Art Unit: 1623  
Date of office action: August 7, 2007  
Date of response: November 6, 2007

226. (Currently amended) The composition ~~pharmaceutical~~  
~~combination~~ of claim 219, wherein the antibody binds to the  
antigen CD20.

227. (Currently amended) The composition ~~pharmaceutical~~  
~~combination~~ of claim 219, wherein the antibody binds to the  
antigen HER2.

228-231. (Canceled)

232. (Currently amended) The composition ~~pharmaceutical~~  
~~combination~~ of claim 219, wherein the amount of the orally  
administered  $\beta$  glucan is about  $\geq 25$  mg/kg/day, five days a  
week for a total of 2-4 weeks.

233-238. (Canceled)